Therapeutic potential of antisense oligodeoxynucleotides in downregulating p53 oncogenic mutations in cancers

Biotechnology Letters

Volumn 33, Issue 2, 2011, Pages 221-228

  Xie, Zhigang ^a   Chng, Wee Joo ^a,b   Tay, Kian Ghee ^a   Liu, Shaw Cheng ^a   Zhou, Jianbiao ^a   Chen, Chien Shing ^a,b,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antisense oligodeoxynucleotide; Carcinoma; Mutation; p53

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDES; ANTISENSE OLIGONUCLEOTIDES; CARCINOMA; CELL VIABILITY; COLONY FORMATION; DOSE-DEPENDENT; GENETIC ALTERATIONS; HEPG2 CELLS; HUMAN CANCER; HUMAN TUMOR CELLS; IN-VIVO SETTING; MUTATION; ONCOGENIC MUTANTS; P53; P53 GENE; P53 MUTANTS; SINGLE NUCLEOTIDES; THERAPEUTIC POTENTIALS; WESTERN-BLOT ANALYSIS; WILD TYPES;

CELL CULTURE; ELECTROPHORESIS; GROWTH KINETICS; OLIGONUCLEOTIDES;

PHARMACODYNAMICS;

ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; MUTANT PROTEIN; PROTEIN P53;

ARTICLE; DRUG ANTAGONISM; GENETICS; HUMAN; METABOLISM; MISSENSE MUTATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; MUTANT PROTEINS; MUTATION, MISSENSE; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78651425783     PISSN: 01415492     EISSN: 15736776     Source Type: Journal    
DOI: 10.1007/s10529-010-0423-5     Document Type: Article

References (26)

1. Beeram M, Patnaik A, Rowinsky EK (2005) Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 23(27): 6771-6790.
2. Blandino G, Levine AJ, Oren M (1999) Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18(2): 477-485.
3. Bullock AN, Fersht AR (2001) Rescuing the function of mutant p53. Nat Rev Cancer 1(1): 68-76.
4. Cadwell C, Zambetti GP (2001) The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 277(1-2): 15-30.
5. Joerger AC, Fersht AR (2007) Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 26(15): 2226-2242.
6. Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ, Belch AR, Pilarski LM (2003) In multiple myeloma, t(4; 14)(p16; q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 101(4): 1520-1529.
7. Lane DP (2005) Exploiting the p53 pathway for the diagnosis and therapy of human cancer. Cold Spring Harb Symp Quant Biol 70: 489-497.
8. Littlejohn JE, Cao X, Miller SD, Ozvaran MK, Jupiter D, Zhang L, Rodarte C, Smythe WR (2008) Bcl-xl antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts. Int J Cancer 123(1): 202-208.
9. Mack GS (2008) Genzyme and Isis strike megadeal. Nat Biotechnol 26(3): 251-253.
10. Martinez LA, Naguibneva I, Lehrmann H, Vervisch A, Tchenio T, Lozano G, Harel-Bellan A (2002) Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci USA 99(23): 14849-14854.
11. Miletti-Gonzalez KE, Chen S, Muthukumaran N, Saglimbeni GN, Wu X, Yang J, Apolito K, Shih WJ, Hait WN, Rodriguez-Rodriguez L (2005) The CD44 receptor interacts with p-glycoprotein to promote cell migration and invasion in cancer. Cancer Res 65(15): 6660-6667.
12. O'Connor OA, Smith EA, Toner LE, Teruya-Feldstein J, Frankel S, Rolfe M, Wei X, Liu S, Marcucci G, Chan KK, Chanan-Khan A (2006) The combination of the proteasome inhibitor bortezomib and the Bcl-2 antisense molecule oblimersen sensitizes human b-cell lymphomas to cyclophosphamide. Clin Cancer Res 12(9): 2902-2911.
13. Opalinska JB, Gewirtz AM (2002) Nucleic-acid therapeutics: basic principles and recent applications. Nat Rev Drug Discov 1(7): 503-514.
14. Ozvaran MK, Cao XX, Miller SD, Monia BA, Hong WK, Smythe WR (2004) Antisense oligonucleotides directed at the Bcl-xl gene product augment chemotherapy response in mesothelioma. Mol Cancer Ther 3(5): 545-550.
15. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2): 74-108.
16. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M (2007) Tp53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26(15): 2157-2165.
17. Sahu NK, Shilakari G, Nayak A, Kohli DV (2007) Antisense technology: a selective tool for gene expression regulation and gene targeting. Curr Pharm Biotechnol 8(5): 291-304.
18. Scian MJ, Stagliano KE, Anderson MA, Hassan S, Bowman M, Miles MF, Deb SP, Deb S (2005) Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol 25(22): 10097-10110.
19. Selivanova G, Wiman KG (2007) Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 26(15): 2243-2254.
20. Sigal A, Rotter V (2000) Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60(24): 6788-6793.
21. Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G (2007) Mutant p53: an oncogenic transcription factor. Oncogene 26(15): 2212-2219.
22. Tamm I, Dorken B, Hartmann G (2001) Antisense therapy in oncology: new hope for an old idea? Lancet 358(9280): 489-497.
23. Vousden KH, Lu X (2002) Live or let die: the cell's response to p53. Nat Rev Cancer 2(8): 594-604.
24. Wacheck V, Zangemeister-Wittke U (2006) Antisense molecules for targeted cancer therapy. Crit Rev Oncol Hematol 59(1): 65-73.
25. Wiman KG (2006) Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ 13(6): 921-926.
26. Xie Z, Choong PF, Poon LF, Zhou J, Khng J, Jasinghe VJ, Palaniyandi S, Chen CS (2008) Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion. Cancer Chemother Pharmacol 62(6): 949-957.